Eintrag weiter verarbeiten
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 35, 2017, 15_suppl, S. e15132-e15132 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Hudgens, Stacie Gable, Jonathon Kulke, Matthew H. Bergsland, Emily Anthony, Lowell Brian Caplin, Martyn E. Oberg, Kjell E. Pavel, Marianne Banks, Phillip Yang, Qi Melissa Lapuerta, Pablo Hudgens, Stacie Gable, Jonathon Kulke, Matthew H. Bergsland, Emily Anthony, Lowell Brian Caplin, Martyn E. Oberg, Kjell E. Pavel, Marianne Banks, Phillip Yang, Qi Melissa Lapuerta, Pablo |
|---|---|
| author |
Hudgens, Stacie Gable, Jonathon Kulke, Matthew H. Bergsland, Emily Anthony, Lowell Brian Caplin, Martyn E. Oberg, Kjell E. Pavel, Marianne Banks, Phillip Yang, Qi Melissa Lapuerta, Pablo |
| spellingShingle |
Hudgens, Stacie Gable, Jonathon Kulke, Matthew H. Bergsland, Emily Anthony, Lowell Brian Caplin, Martyn E. Oberg, Kjell E. Pavel, Marianne Banks, Phillip Yang, Qi Melissa Lapuerta, Pablo Journal of Clinical Oncology Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. Cancer Research Oncology |
| author_sort |
hudgens, stacie |
| spelling |
Hudgens, Stacie Gable, Jonathon Kulke, Matthew H. Bergsland, Emily Anthony, Lowell Brian Caplin, Martyn E. Oberg, Kjell E. Pavel, Marianne Banks, Phillip Yang, Qi Melissa Lapuerta, Pablo 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15132 <jats:p> e15132 </jats:p><jats:p> Background: Telotristat ethyl is a tryptophan hydroxylase inhibitor in development for the treatment of carcinoid syndrome (CS) in patients who receive somatostatin analog (SSA) therapy. In TELESTAR, a pivotal Phase 3 study, telotristat ethyl significantly reduced bowel movement (BM) frequency compared to placebo. The objective of this study was to psychometrically assess meaningful change in BM frequency using data collected within the TELESTAR study. Methods: An anchor-based approach consisted of mapping change from baseline in BM frequency to other patient reported assessments of change. These included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) Diarrhea Symptom responders, the EORTC GI.NET21 GI Symptom responders, and patient reported adequate relief at Week 12 (responders had a ≥ 10-point decrease in scores from Day 1 to Week 12). Parameters included within group mean change from baseline to Week 12, t-tests of the change (Wilcoxon Rank Sum for adequate relief), effect size (ES: calculated as the difference between mean on-treatment and baseline BM frequency, divided by the standard deviation of the baseline), and related confidence intervals. Results: There were 135 patients with CS, with a mean age of 63.6 years and mean baseline BM frequency of 5.7 BM/day. Anchor-based analyses indicated significant differences in BM frequency between adequate relief groups at Week 12 (ES: −1.58 vs. −0.79; p = 0.014), responders and non-responders on the EORTC QLQ-C30 Diarrhea Symptoms domain (ES: −1.24 vs. −0.59; p < 0.0001), and responders and non-responders on the EORTC GI.NET21 GI Symptoms Domain (ES: −1.49 vs. −0.75; p = 0.0053). These corresponded to BM frequency reductions of 1.7–1.9 BM/day, or ≥ 30%. Conclusions: Results of this study indicated that patients with CS experienced clinically meaningful reductions in BM frequency of ≥ 30% over the course of 12 weeks. Clinical trial information: NCT01677910. </jats:p> Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2017.35.15_suppl.e15132 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC5lMTUxMzI |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC5lMTUxMzI |
| institution |
DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 |
| imprint |
American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2017 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
hudgens2017evaluationofmeaningfulchangeinbowelmovementfrequencyforpatientswithcarcinoidsyndrome |
| publishDateSort |
2017 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_unstemmed |
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_full |
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_fullStr |
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_full_unstemmed |
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_short |
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_sort |
evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15132 |
| publishDate |
2017 |
| physical |
e15132-e15132 |
| description |
<jats:p> e15132 </jats:p><jats:p> Background: Telotristat ethyl is a tryptophan hydroxylase inhibitor in development for the treatment of carcinoid syndrome (CS) in patients who receive somatostatin analog (SSA) therapy. In TELESTAR, a pivotal Phase 3 study, telotristat ethyl significantly reduced bowel movement (BM) frequency compared to placebo. The objective of this study was to psychometrically assess meaningful change in BM frequency using data collected within the TELESTAR study. Methods: An anchor-based approach consisted of mapping change from baseline in BM frequency to other patient reported assessments of change. These included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) Diarrhea Symptom responders, the EORTC GI.NET21 GI Symptom responders, and patient reported adequate relief at Week 12 (responders had a ≥ 10-point decrease in scores from Day 1 to Week 12). Parameters included within group mean change from baseline to Week 12, t-tests of the change (Wilcoxon Rank Sum for adequate relief), effect size (ES: calculated as the difference between mean on-treatment and baseline BM frequency, divided by the standard deviation of the baseline), and related confidence intervals. Results: There were 135 patients with CS, with a mean age of 63.6 years and mean baseline BM frequency of 5.7 BM/day. Anchor-based analyses indicated significant differences in BM frequency between adequate relief groups at Week 12 (ES: −1.58 vs. −0.79; p = 0.014), responders and non-responders on the EORTC QLQ-C30 Diarrhea Symptoms domain (ES: −1.24 vs. −0.59; p < 0.0001), and responders and non-responders on the EORTC GI.NET21 GI Symptoms Domain (ES: −1.49 vs. −0.75; p = 0.0053). These corresponded to BM frequency reductions of 1.7–1.9 BM/day, or ≥ 30%. Conclusions: Results of this study indicated that patients with CS experienced clinically meaningful reductions in BM frequency of ≥ 30% over the course of 12 weeks. Clinical trial information: NCT01677910. </jats:p> |
| container_issue |
15_suppl |
| container_start_page |
0 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
35 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792325210370736142 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:01:58.646Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Evaluation+of+meaningful+change+in+bowel+movement+frequency+for+patients+with+carcinoid+syndrome.&rft.date=2017-05-20&genre=article&issn=1527-7755&volume=35&issue=15_suppl&pages=e15132-e15132&jtitle=Journal+of+Clinical+Oncology&atitle=Evaluation+of+meaningful+change+in+bowel+movement+frequency+for+patients+with+carcinoid+syndrome.&aulast=Lapuerta&aufirst=Pablo&rft_id=info%3Adoi%2F10.1200%2Fjco.2017.35.15_suppl.e15132&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792325210370736142 |
| author | Hudgens, Stacie, Gable, Jonathon, Kulke, Matthew H., Bergsland, Emily, Anthony, Lowell Brian, Caplin, Martyn E., Oberg, Kjell E., Pavel, Marianne, Banks, Phillip, Yang, Qi Melissa, Lapuerta, Pablo |
| author_facet | Hudgens, Stacie, Gable, Jonathon, Kulke, Matthew H., Bergsland, Emily, Anthony, Lowell Brian, Caplin, Martyn E., Oberg, Kjell E., Pavel, Marianne, Banks, Phillip, Yang, Qi Melissa, Lapuerta, Pablo, Hudgens, Stacie, Gable, Jonathon, Kulke, Matthew H., Bergsland, Emily, Anthony, Lowell Brian, Caplin, Martyn E., Oberg, Kjell E., Pavel, Marianne, Banks, Phillip, Yang, Qi Melissa, Lapuerta, Pablo |
| author_sort | hudgens, stacie |
| container_issue | 15_suppl |
| container_start_page | 0 |
| container_title | Journal of Clinical Oncology |
| container_volume | 35 |
| description | <jats:p> e15132 </jats:p><jats:p> Background: Telotristat ethyl is a tryptophan hydroxylase inhibitor in development for the treatment of carcinoid syndrome (CS) in patients who receive somatostatin analog (SSA) therapy. In TELESTAR, a pivotal Phase 3 study, telotristat ethyl significantly reduced bowel movement (BM) frequency compared to placebo. The objective of this study was to psychometrically assess meaningful change in BM frequency using data collected within the TELESTAR study. Methods: An anchor-based approach consisted of mapping change from baseline in BM frequency to other patient reported assessments of change. These included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) Diarrhea Symptom responders, the EORTC GI.NET21 GI Symptom responders, and patient reported adequate relief at Week 12 (responders had a ≥ 10-point decrease in scores from Day 1 to Week 12). Parameters included within group mean change from baseline to Week 12, t-tests of the change (Wilcoxon Rank Sum for adequate relief), effect size (ES: calculated as the difference between mean on-treatment and baseline BM frequency, divided by the standard deviation of the baseline), and related confidence intervals. Results: There were 135 patients with CS, with a mean age of 63.6 years and mean baseline BM frequency of 5.7 BM/day. Anchor-based analyses indicated significant differences in BM frequency between adequate relief groups at Week 12 (ES: −1.58 vs. −0.79; p = 0.014), responders and non-responders on the EORTC QLQ-C30 Diarrhea Symptoms domain (ES: −1.24 vs. −0.59; p < 0.0001), and responders and non-responders on the EORTC GI.NET21 GI Symptoms Domain (ES: −1.49 vs. −0.75; p = 0.0053). These corresponded to BM frequency reductions of 1.7–1.9 BM/day, or ≥ 30%. Conclusions: Results of this study indicated that patients with CS experienced clinically meaningful reductions in BM frequency of ≥ 30% over the course of 12 weeks. Clinical trial information: NCT01677910. </jats:p> |
| doi_str_mv | 10.1200/jco.2017.35.15_suppl.e15132 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC5lMTUxMzI |
| imprint | American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2017 |
| institution | DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:01:58.646Z |
| match_str | hudgens2017evaluationofmeaningfulchangeinbowelmovementfrequencyforpatientswithcarcinoidsyndrome |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | e15132-e15132 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Hudgens, Stacie Gable, Jonathon Kulke, Matthew H. Bergsland, Emily Anthony, Lowell Brian Caplin, Martyn E. Oberg, Kjell E. Pavel, Marianne Banks, Phillip Yang, Qi Melissa Lapuerta, Pablo 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15132 <jats:p> e15132 </jats:p><jats:p> Background: Telotristat ethyl is a tryptophan hydroxylase inhibitor in development for the treatment of carcinoid syndrome (CS) in patients who receive somatostatin analog (SSA) therapy. In TELESTAR, a pivotal Phase 3 study, telotristat ethyl significantly reduced bowel movement (BM) frequency compared to placebo. The objective of this study was to psychometrically assess meaningful change in BM frequency using data collected within the TELESTAR study. Methods: An anchor-based approach consisted of mapping change from baseline in BM frequency to other patient reported assessments of change. These included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) Diarrhea Symptom responders, the EORTC GI.NET21 GI Symptom responders, and patient reported adequate relief at Week 12 (responders had a ≥ 10-point decrease in scores from Day 1 to Week 12). Parameters included within group mean change from baseline to Week 12, t-tests of the change (Wilcoxon Rank Sum for adequate relief), effect size (ES: calculated as the difference between mean on-treatment and baseline BM frequency, divided by the standard deviation of the baseline), and related confidence intervals. Results: There were 135 patients with CS, with a mean age of 63.6 years and mean baseline BM frequency of 5.7 BM/day. Anchor-based analyses indicated significant differences in BM frequency between adequate relief groups at Week 12 (ES: −1.58 vs. −0.79; p = 0.014), responders and non-responders on the EORTC QLQ-C30 Diarrhea Symptoms domain (ES: −1.24 vs. −0.59; p < 0.0001), and responders and non-responders on the EORTC GI.NET21 GI Symptoms Domain (ES: −1.49 vs. −0.75; p = 0.0053). These corresponded to BM frequency reductions of 1.7–1.9 BM/day, or ≥ 30%. Conclusions: Results of this study indicated that patients with CS experienced clinically meaningful reductions in BM frequency of ≥ 30% over the course of 12 weeks. Clinical trial information: NCT01677910. </jats:p> Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. Journal of Clinical Oncology |
| spellingShingle | Hudgens, Stacie, Gable, Jonathon, Kulke, Matthew H., Bergsland, Emily, Anthony, Lowell Brian, Caplin, Martyn E., Oberg, Kjell E., Pavel, Marianne, Banks, Phillip, Yang, Qi Melissa, Lapuerta, Pablo, Journal of Clinical Oncology, Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome., Cancer Research, Oncology |
| title | Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_full | Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_fullStr | Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_full_unstemmed | Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_short | Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_sort | evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| title_unstemmed | Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15132 |